US OptionsDetailed Quotes
PFE241115P39000
- 12.60
- 0.000.00%
15min DelayClose Nov 14 16:00 ET
0.00High0.00Low
12.60Open12.60Pre Close0 Volume0 Open Interest39.00Strike Price0.00Turnover373.51%IV-1.46%PremiumNov 15, 2024Expiry Date12.98Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9854Delta0.0081Gamma2.00Leverage Ratio-0.0885Theta-0.0006Rho-1.97Eff Leverage0.0005Vega
Pfizer Stock Discussion
Sign in to post a comment
$Pfizer (PFE.US)$ everyday I feel I buy it dip, but the coming day it just dipper.
4
3
$Pfizer (PFE.US)$
what now??🤣🤣
what now??🤣🤣
1
1
$Pfizer (PFE.US)$ perhaps the biggest question for this company is: how will it surpass the annual 60B revenue? We have seen this revenue on the last decade, but to say this company has no bottom I think it's purely sentimental and irrational, IMO I would bet $15 - $20 is market for crash scenario (IF any)
otherwise it would stay in $22 - $31 range like going around in circle
IMO only, it may upset some people, sorry for that
otherwise it would stay in $22 - $31 range like going around in circle
IMO only, it may upset some people, sorry for that
2
$Pfizer (PFE.US)$ this is the bottom
5
$Pfizer (PFE.US)$ SALE!!!
3
$Pfizer (PFE.US)$
Pfizer (PFE) is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist investor Starboard Value, looks to divest non-core assets, according to three people familiar with the matter.
The unit, now called Pfizer Hospital, was formed after Pfizer bought Hospira for about $17 billion in 2015. The pharma giant has hired Goldman Sachs to gauge initial interest from potential buyers, which include private equity firms and other phar...
Pfizer (PFE) is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist investor Starboard Value, looks to divest non-core assets, according to three people familiar with the matter.
The unit, now called Pfizer Hospital, was formed after Pfizer bought Hospira for about $17 billion in 2015. The pharma giant has hired Goldman Sachs to gauge initial interest from potential buyers, which include private equity firms and other phar...
1
No comment yet
QMengColdJoke : PFE is already very strong in pharmaceutical stocks. Because it is very cheap.
friendly Ibex_1450 : Like me
Unaware : Great opportunity to get on board.